Consumer guides — for Switzerland

Everything you need day-to-day — from safe buying and correct storage to travel rules and drug testing.

The guide series walks beginners, athletes, parents and doctors through selection, dosage, safety and law. Every guide ends with a concrete recommendation, a linked tool (price calculator, THC detection) and emergency contacts — plus a compact glossary and cross-links into the medical and legal hubs.

Definition and context

Our guides address specific purchasing decisions: which cultivation method, active ingredient ratio, price per unit of active ingredient, and quality certificates are required.

The situation in Switzerland

The Swiss market can be confusing because identical products can cost two to three times as much depending on the sales channel. That is why our guides consistently calculate the price per gram or per 100 mg of CBD instead of package prices.

What this means in practice

The most important rule for any purchase: request the batch certificate, check the total THC, and verify the cultivation method and harvest date. Following these three steps will already eliminate the vast majority of problematic products.

Frequently asked questions

What is the first thing I should look for when buying CBD?

The certificate of analysis for the specific batch, showing a total THC content of under 1%.

How do I make a fair comparison between CBD oils?

By comparing the price per 100 mg of CBD, not just the price per bottle or the percentage alone.

Is it worth buying in larger quantities?

In terms of price, usually yes, provided they are stored correctly: in a cool, dark, airtight place at 55–62% relative humidity.

Background and development

Switzerland's cannabis landscape underwent a paradigm shift under the Federal Narcotics Act (BetmG). Since 2011, cannabis with under 1.0% THC is legally classified as industrial hemp, catalyzing a massive over-the-counter CBD market overseen by the Federal Office of Public Health (FOPH/BAG) and Swissmedic. On 1 August 2022, the Swiss parliament liberalized medical cannabis, removing the need for an exceptional BAG permit and allowing doctors to prescribe medical THC directly. Simultaneously, the country embarked on pioneering, strictly regulated recreational pilot studies (such as Züri Can in Zurich, Weed Care in Basel, and projects in Bern, Lausanne, and Geneva) to evaluate controlled distribution models. Today, Switzerland stands at a crossroads: while the 1% THC limit remains a unique European threshold, consumers must navigate a complex, decentralized market regulated across 26 cantons, where product safety standards must be carefully balanced against evolving municipal rules and federal directives.

Distinctions and misconceptions

Consumers frequently confuse the legal rules governing CBD with those of regulated THC. A common misconception is that possession of low-THC cannabis (under 1%) is completely unregulated; in reality, police can still seize looks-alike flowers for testing. Conversely, possessing up to 10 grams of high-THC cannabis for personal use is decriminalized under the BetmG and punished only by a CHF 100 fixed penalty (Ordnungsbusse), not a criminal record. Another critical point of confusion involves road traffic laws. Many assume consuming legal CBD is safe before driving, but even minor trace elements can easily push a driver over the strict Swiss analytical zero limit of 1.5 micrograms of THC per liter of blood. Finally, medical prescriptions must not be confused with recreational pilot study access; the former requires a specific medical diagnosis, whereas the latter is a localized scientific study requiring registration in participating cantons.

Decision guide for Switzerland

When navigating the Swiss market, an adult must employ systematic checks to ensure product integrity and compliance. Start by validating the regulatory category: is the product registered as a tobacco substitute, a cosmetic, or an ingredient? Demand a batch-specific laboratory certificate (Certificate of Analysis) to verify the exact cannabinoids and ensure the total THC remains strictly under the 1.0% legal threshold. Avoid products with vague labels, missing manufacturer details, or exaggerated health claims, which violate Swissmedic regulations. Price-wise, bypass raw package costs and calculate the cost per milligram of active ingredient to spot unfair markups, as identical products vary wildly across retail pharmacies, kiosks, and specialized clubs. For high-THC options, verify if you qualify for the medical pathway under a Swiss-registered doctor or if you reside in a canton running an active pilot study. Ensure all purchases are backed by transparent cultivation methods.

What are the legal limits and penalties for carrying high-THC cannabis in Switzerland?

Under the Federal Narcotics Act (BetmG), possessing up to 10 grams of cannabis with over 1% THC for personal consumption is not a criminal offense for adults. If caught by police, it is penalized with a fixed administrative fine of CHF 100, provided no other infractions are committed. However, carrying any amount across Swiss national borders remains strictly prohibited and subject to criminal prosecution under customs regulations.

Can I legally drive in Switzerland after consuming legal CBD products?

Driving after consuming CBD is highly risky. Switzerland enforces a strict limit of 1.5 micrograms of THC per liter of blood for driving. Because legal Swiss CBD products can contain up to 1% THC, regular or heavy consumption can easily accumulate enough THC in your system to exceed this analytical threshold, leading to severe penalties, license suspension, and criminal charges.

Explore this topic further

These guides explain the background and address practical questions in the Swiss context.

Key figures

  • 220’000+ — Swiss adults regularly consume cannabis (BAG · Suchtmonitoring 2024)
  • 36% — of 15–34 year-olds have tried cannabis (EMCDDA · Country Report Switzerland 2024)
  • CHF 582M — estimated Swiss cannabis black-market revenue per year (Uni Genf · Cannabis Market Estimate 2023)
  • 7 — cities with active or approved pilot projects (BAG · Cannabis Pilotversuche 2026)

Current research

  • Cannabis use in Switzerland — Addiction Monitoring 2024 — Sucht Schweiz, BAG · 2024
  • European Drug Report — Cannabis Chapter — EMCDDA, EUDA · 2024
  • WHO Expert Committee on Drug Dependence — Cannabis Review — WHO ECDD, WHO · 2023

Datasets on this topic